Home › Funds › Privium Fund Management B.V. › LXEO
Privium Fund Management B.V. position in LXEO
LEXEO THERAPEUTICS INC · Health Care
Privium Fund Management B.V. reported holding 155,000 shares of LXEO (LEXEO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$524K, representing 0.10% of its reported portfolio and ranking #47 among its reported holdings. Privium Fund Management B.V. has disclosed LXEO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Privium Fund Management B.V.'s LXEO position evolved
Privium Fund Management B.V. first disclosed a stake in LXEO in Q4 2024 at 138,115 shares (US$909K). The position peaked in Q4 2025 at 192,550 shares, worth US$1.9M. Across 8 filings, Privium Fund Management B.V. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 155,000 shares valued at US$524K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 138.12K | $908.80K | New |
| Q1 2025 | 160.20K | $555.89K | Add |
| Q2 2025 | 178.36K | $752.66K | Add |
| Q3 2025 | 192.36K | $1.28M | Add |
| Q4 2025 | 192.55K | $1.91M | Hold |
| Q1 2026 | 205.00K | $1.18M | Add |
| Q2 2026 | 155.00K | $722.30K | Reduce |
| Q3 2026 | 155.00K | $523.90K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LXEO and 13F data
LXEO (LEXEO THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LXEO
- MONTANOVA CAPITAL, LLC 6.38M sh · $29.72M · Q2 2026
- Affinity Asset Advisors, LLC 5.81M sh · $27.03M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.82M sh · $22.46M · Q2 2026
- Vestal Point Capital, LP 4.32M sh · $20.11M · Q2 2026
- Paradigm Biocapital Advisors LP 4.18M sh · $19.44M · Q2 2026
- 683 Capital Management, LLC 1.88M sh · $8.73M · Q2 2026
- Avoro Capital Advisors LLC 1.49M sh · $6.93M · Q2 2026
- Spruce Street Capital LP 928.59K sh · $4.32M · Q2 2026
- Jones Hill Capital LP 593.74K sh · $2.01M · Q3 2026
- DAFNA Capital Management LLC 377.06K sh · $1.76M · Q2 2026
More on Privium Fund Management B.V.
FAQ
How long has Privium Fund Management B.V. held LXEO?
Privium Fund Management B.V. has disclosed LXEO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Privium Fund Management B.V.'s current position in LXEO?
As of Q3 2026, Privium Fund Management B.V. holds 155.00K shares of LXEO (LEXEO THERAPEUTICS INC), valued at $523.90K, representing 0.10% of its reported portfolio and ranking #47.
Has Privium Fund Management B.V. been buying or selling LXEO?
In the latest 13F filing (Q3 2026), Privium Fund Management B.V. held unchanged its position in LXEO. The position peaked in Q4 2025 at 192.55K shares.
Which other funds hold LXEO?
Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.